Ergoteles’s Connect Biopharma Holdings CNTB Stock Holding History

Ergoteles’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-44,297	Closed	-$38.4K	–	1335
2022 Q4	$38.4K	Buy	+44,297	New	+$36.5K	﹤0.01%	1318

Other funds holding CNTB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ergoteles's CNTB Position: Q1 2023 in Review

Ergoteles sold out of Connect Biopharma Holdings (CNTB) in Q1 2023, closing a stake of 44,297 shares — an estimated $38.4K sold.

Ergoteles first reported a position in CNTB in Q4 2022 and held it in 1 quarter. The position peaked at $38.4K in Q4 2022. 16 funds tracked by Wall St. Rank hold CNTB as of Q1 2023.

Ergoteles reported no remaining Connect Biopharma Holdings position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 44,297 Connect Biopharma Holdings shares in Q1 2023, an estimated $38.4K.
Ergoteles first reported a position in Connect Biopharma Holdings in Q4 2022 and held it in 1 quarter.
Ergoteles's Connect Biopharma Holdings position peaked at $38.4K in Q4 2022.
16 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.